| Revenue growth | FY26 consolidated revenue reached ₹142cr; 10% domestic growth. |
|---|---|
| Margins | Consolidated EBITDA at 40%; Co-Res margins currently lower. |
| Demand visibility | Strong demand in oncology and AMR; seasonal flu impacts domestic. |
| Management confidence | Confident in international expansion; optimistic about US FDA outcomes. |
Growth
Consolidated growth supported by Co-Res and TruPCR Europe; domestic growth slowed to 7-10% due to base effects and competition.
Outlook
Management guides for 15-20% consolidated revenue and EBITDA growth for FY27, targeting US FDA clearance for AMR products.
Risks
Intense Chinese competition in respiratory products and high employee costs in Belgium (Co-Res) impacting consolidated EBITDA margins.
Earnings Call filed with BSE, NSE: 3BBLACKBIO. Summary written with AI assistance from the document.
3B BlackBio Dx Ltd: key numbers
- Share price
- ₹1,463.50
- Market cap
- ₹1,256 Cr
- Revenue (annual)
- ₹141.9 Cr
- Net profit (annual)
- ₹58.59 Cr
- P/E (TTM)
- 22.6×Sector 37.5×
- Promoter holding
- 40.95%+0.01% QoQ
- FII holding
- 2.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from 3B BlackBio Dx Ltd
All →3B BlackBio Dx Other Announcement
3B BlackBio Dx sent a Reg 36(1)(b) letter to shareholders providing the weblink to its FY 2025-26 Annual Report ahead of the 54th AGM. No financial figures or business events are disclosed.
3B BlackBio Dx Annual Report
3B BlackBio Dx Ltd filed its FY 2025-26 Annual Report with BSE under Regulation 34(1). The report recaps its molecular diagnostics growth and global expansion.
3B BlackBio Dx Annual General Meeting
3B BlackBio Dx Ltd issued notice for its 54th AGM on 29 September 2026. Proposed business includes FY26 financials adoption and Rs.5 per share final dividend.
3B BlackBio Dx Investor Presentation: Key Takeaways
3B BlackBio Dx reported Q1FY27 consolidated revenue of ₹33.49 Cr, up 50% YoY, driven by the Coris BioConcept acquisition. Core MDx business grew 17.4% excluding Coris.
- Call
- Guides 18% growth
3B BlackBio Dx Q1 FY27 Results: Net Profit ₹9 Cr, Down 28.6% YoY
3B BlackBio Dx Ltd reported revenue from operations of ₹33.5 Cr (+50.9% YoY) and net profit of ₹9 Cr (-28.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹9 Cr · -28.6% YoY
3B BlackBio Dx Earnings Call: Key Takeaways
3B BlackBio reported FY26 consolidated revenue of ₹142 cr and PAT of ₹60 cr, driven by diagnostic growth and contributions from Coris BioConcept and TRUPCR Europe.